Next Article in Journal
The Hippo Pathway: Immunity and Cancer
Next Article in Special Issue
Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond
Previous Article in Journal
Loss of One or Two PATZ1 Alleles Has a Critical Role in the Progression of Thyroid Carcinomas Induced by the RET/PTC1 Oncogene
Previous Article in Special Issue
The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessFeature PaperReview
Cancers 2018, 10(4), 93; https://doi.org/10.3390/cancers10040093

The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas

1
Ludwig Boltzmann Institute for Cancer Research, 1090 Vienna, Austria
2
Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210 Vienna, Austria
3
Clinical Institute of Pathology, Medical University of Vienna, 1090 Vienna, Austria
4
Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB21QP, UK
Co-first authors.
Co-last authors.
*
Author to whom correspondence should be addressed.
Received: 22 February 2018 / Revised: 21 March 2018 / Accepted: 25 March 2018 / Published: 28 March 2018
Full-Text   |   PDF [5147 KB, uploaded 3 May 2018]   |  

Abstract

The Activator Protein-1 (AP-1) transcription factor (TF) family, composed of a variety of members including c-JUN, c-FOS and ATF, is involved in mediating many biological processes such as proliferation, differentiation and cell death. Since their discovery, the role of AP-1 TFs in cancer development has been extensively analysed. Multiple in vitro and in vivo studies have highlighted the complexity of these TFs, mainly due to their cell-type specific homo- or hetero-dimerization resulting in diverse transcriptional response profiles. However, as a result of the increasing knowledge of the role of AP-1 TFs in disease, these TFs are being recognized as promising therapeutic targets for various malignancies. In this review, we focus on the impact of deregulated expression of AP-1 TFs in CD30-positive lymphomas including Classical Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma. View Full-Text
Keywords: Activator Protein-1 (AP-1); Transcription Factors (TFs); Anaplastic Large Cell Lymphoma (ALCL); CD-30; Classical Hodgkin Lymphoma (CHL); Peripheral T-cell Lymphoma (PTCL) Activator Protein-1 (AP-1); Transcription Factors (TFs); Anaplastic Large Cell Lymphoma (ALCL); CD-30; Classical Hodgkin Lymphoma (CHL); Peripheral T-cell Lymphoma (PTCL)
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Garces de los Fayos Alonso, I.; Liang, H.-C.; Turner, S.D.; Lagger, S.; Merkel, O.; Kenner, L. The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas. Cancers 2018, 10, 93.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top